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Background: Standard therapy for patients with stage I-III squamous cell carcinoma (SCC) of the anal canal is
chemo-radiotherapy with 5-fluorouracil (5-FU) and mitomycin C (MMC). While there is limited published evidence
to substitute capecitabine (CAP) for 5-FU, the objectives of the study were to describe the toxicity, dose intensity
and outcomes of a sequential cohort of patients treated with chemo-radiotherapy with CAP and MCC in a
population-based setting.
Methods: Patients with stage I-III malignancies of the anal canal referred between February 2010 and March 2012
were included. Dose intensity was calculated by comparing delivered versus planned radiation and chemotherapy
treatments and toxicity was retrospectively graded according to standard protocol-specified criteria.
Results: Among 66 eligible patients, median planned dose of radiation was 51.9 Gy over 5.5 weeks, range 25.0 to
63 Gy, and dose intensity was 98%. Median delivered dose of MCC delivered was 12 mg/m2 on day one, week one
while median CAP dose was 825 mg/m2 twice daily on radiation days. CAP dose reductions due to toxicity were
recorded for 13 patients (20%). Median follow-up was 20 months and 94% of patients with squamous cell histology
had no evidence of relapse.
Conclusions: Chemo-radiation with CAP plus MMC is well tolerated and may be a reasonable consideration for
patients with stage I-III SCC of the anal canal. A range of planned radiation dose was observed and longer follow-up is
necessary to ensure that patients who received lower doses of radiation have similar outcomes to those who received
larger doses.
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Carcinoma of the anal canal is a relatively uncommon
malignancy, accounting for approximately 2.5 percent of
all gastrointestinal cancers [1]. The incidence of this dis-
ease has been on the rise for the past few decades [2],
which is thought to be due, in part, to the increased sex-
ual transmission of human papilloma virus (HPV) [3,4].
Squamous cell carcinoma (SCC) of the anal canal re-
mains the only carcinoma of the gastrointestinal tract that
is curable without the need for definitive surgery, with
5 year survival rates nearing 90% for early stage disease* Correspondence: hkennecke@bccancer.bc.ca
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unless otherwise stated.[2,3,5,6]. Treatment regimens for SCC of the anal canal
have evolved over the past decades, and studies have in-
cluded comparisons of radiotherapy alone versus chemora-
diation [7-9]; determining treatment benefits of mitomycin
C (MMC) [10,11]; and comparisons of MMC with cisplatin
[6,12-15]. The accepted current standard regimen for pa-
tients with stage I-III SCC of the anal canal is radiotherapy
(50.4 Gy) with concurrent infusional 5-fluorouracil (5-FU)
administered days one through four during weeks one and
five and MMC administered on day one of week one. Sub-
stitution of MMC for cisplatin on days one and 29 of radi-
ation has been shown equally efficacious and associated
with significantly less hematologic toxicity [6].
Capecitabine (Cap) is an oral fluoropyrimidine shown
to be equivalent to infusional 5-FU when given concurrentlytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rectal adenocarcinoma [16-18]. Unlike 5-FU, which is
intravenously infused, Cap is orally administered which
provides resource benefits as it is more convenient for
patients and staff and does not require the use of a cen-
tral venous infusional device. There is only limited evi-
dence to support the substitution of infusional 5-FU for
capecitabine in the treatment of SCC of the anal canal.
In a previously published phase II study, thirty-one pa-
tients with stage I-III SCC of the anal canal were treated
with continuous radiation, Cap on radiation days and
MMC on day 1 [19]. A total of 24 (77%) of patients had
a complete clinical response after four weeks, while 3
(16%) had a partial response. Three locoregional re-
lapses occurred during the follow up period (median of
14 months) [19].
In this study, a retrospective chart review was con-
ducted of a sequential cohort of patients with stage I-III
SCC of the anal canal treated with standard radiation
and concurrent Cap and MMC according to a standard
province-wide protocol [20]. The objectives of the study
were to: (1) describe the dose intensity of radiation, Cap
and MMC by comparing the planned versus the delivered
dose of radiation, Cap and MMC; (2) describe treatment-
related patient toxicities and (3) describe the early out-
comes of therapy.
Methods
Treatment of SCC of the anal canal
Patients were treated at one of five cancer treatment cen-
ters throughout the province of British Columbia (BC),
a Canadian province with a population of 4.4 million.
The BC Cancer Agency (BCCA) is responsible for fund-
ing all systemic cancer therapy and is the sole provider
of radiotherapy in BC. All patients in the province who
require radiation therapy for a diagnosis of SCC anal
cancer are referred to the BCCA for consultation and
treatment delivery.
Chemoradiation was delivered according to GICART,
a standardized protocol, introduced in February 2010
and posted on the BCCA website [20]. Eligibility criteria
for this therapy include a diagnosis of stage I-III squa-
mous cell or cloacogenic carcinoma of the anal canal
and ECOG performance status of less than or equal to 2.
Patients also need to have an adequate marrow reserve
(ANC greater than or equal to 1.5 × 109/L, platelets
greater than 100 × 109/L), with adequate renal (creatin-
ine less than or equal to 1.5 × ULN) and liver function
(bilirubin less than or equal to 26 μmol/L; AST/Alkaline
Phosphatase less than or equal to 5 × ULN).
Patients treated under the GICART protocol received
a combination of chemotherapy and radiotherapy. Con-
tinuous radiation at a dose of 50.4 Gy in 28 fractions over
5 1/2 weeks was recommended. Chemotherapy with Capwas delivered twice a day at a dose of 825 mg/m2 on days
that radiotherapy was administered (days 1–5, 8–12, 15–
19, 22–26, 29–33, 36–40), to a total daily dose of
1650 mg/m2. As specified in the GICART protocol, Cap
was administered orally with food, with the second dose
administered 10–12 hours after the first. MMC is ad-
ministered on day one week one intravenously, at a dose
of 12 mg/m2 to a maximum dose of 20 mg.
Study cohort selection and data extraction
All SCC anal cancer patients diagnosed at BCCA and
treated with GICART protocol from the time of its
introduction in February 1, 2010 until March 29, 2012
were included in this study.
The charts from all SCC anal canal patients in this co-
hort were used to determine variations in chemotherapy
doses, differences in radiation dosing and type of radi-
ation technique delivered to each patient. Patient out-
comes including relapses and deaths were documented
until April 2013. To determine the levels of toxicity ex-
perienced by each patient in the cohort, a review was
conducted of all the narratives dictated by the oncologist
assigned to each patient. Nausea, vomiting, stomatitis
and diarrhea toxicities were graded according to the
GICART protocol. Dermatitis data was extrapolated
from the narratives provided by the physicians and a
graded according to the Dermatitis Grading Scale from
the BCCA Care of Radiation Skin Reactions standard
[21]. The most severe toxicity described for each pa-
tient was used in each case. For example, if a patient
had grade 3 diarrhea but was experiencing grade 4 levels
of nausea, they were classified as experiencing a grade 4
toxicity.
Sources of research support
The Provincial Pharmacy Database was used to identify
eligible patients, and patient and tumor characteristics
were identified through the BCCA Gastrointestinal Cancer
Outcomes Unit (GICOU). The GICOU database prospect-
ively documents standard pathologic and clinical criteria
of patients referred to the BCCA. The study was con-
ducted as a quality assurance initiative and was reviewed




The characteristics and diagnostic status of the 66 pa-
tients included in this study are shown in Table 1. The
majority of patients were female (62%), HIV negative
(99%), non-smokers (74%) and non-drinkers (74%). Most
patients (n = 61, 93%) presented with an ECOG status
between 0–1, while three (5%) presented with an ECOG
Table 1 Characteristics of patients included in study
(n = 66)
Characteristics Number of patients (percent)

























Squamous cell carcinoma 49 (74%)
Squamous carcinoma (keratinizing) 8 (12%)
Squamous cell carcinoma (basaloid) 5 (8%)
Tubulovillous adenoma 2 (3%)
Adenocarcinoma 2 (3%)
Characteristics of all 66 patients included in the study are shown above, both
as a total number and as a percentage of study participants.
Table 2 Chemotherapy dosings (n = 66) as a total number
and as a percentage
Capecitabine dose administered Number of patients (percent)
Number of patients starting at full dose (750–825 mg/m2)
- No subsequent dose reduction 59 (78%)
- Dose reduction 13 (22%)
- Discontinuation 0 (0%)
Number of patients starting at dose level −1 (500–749 mg/m2)
- Received 7 (11%)
- Dose reduction 0 (0%)
- Discontinuation 0 (0%)
Mean weeks of capectiabine 5.5 (2.5-6)
Mitomycin dose administered Number of patients (percent)
- Full dose (12 mg/m2) 63 (95%)
- Dose level −1 3 (5%)
The capecitabine and mitomycin dose administered to patients in the study,
both as a total number and as a percentage of study participants.
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3. Staging was varied, as 26 patients (39%) presented
with a stage I tumor, 15 (23%) presented with a stage II
tumor and 25 (38%) presented with a stage III tumor.
Histologically, the tumours were classified as follows:
of 66 patients, 62 (94%) had squamous cell carcinoma of
which eight were described as keratinizing, and five as
basaloid. Two patients (3%) had tubulovillous adenoma,
and an additional two patients (3%) had adenocarcin-
oma. All 66 patients were included in the dose intensity
and toxicity analysis, while only patients with SCC (62)
were included in the outcome analysis.Treatment dose intensity
All patients included in the study initiated therapy with
both capecitabine and mitomycin C. The doses adminis-
tered are shown in Table 2, along with the number of
dose reductions, increases, omissions, and discontinua-
tions for each therapy administered.
Patients received a median dose of 825 mg/m2 of Cap
administered twice daily on radiation days. Dose reduc-
tions were recorded for 13 patients (20%) due to appar-
ent toxicity during treatment. There were no recorded
increases, omissions or discontinuations for this drug.
The median duration of therapy of capecitabine was five
and a half weeks on week-days, with a treatment range
from three to six weeks. Seven patients initiated therapy
at a lower dose of Cap (500–749 mg/m2) due to varying
issues ranging from patient comorbidities, previous
chemotherapy treatment, and the use of therapy purely
for palliative purposes. None of the patients starting at
this lower dose required a subsequent dose reduction.
The median dose of MCC delivered was 12 mg/m2 on
day one, week one. Pre-planned dose reductions were re-
corded for three (5%) of patients, of which two cases
were due to patient co-morbidities and one was due to
an infusion reaction.
The radiation dose, technique and treatment duration
received by patients in this cohort is shown in Table 3.
Median planned dose of radiation was 51.9 Gy over a
median of 5.5 weeks, range 25.0 to 63 Gy. Comparing
the planned versus delivered radiotherapy doses, we can
see that the majority (98%) of patients received the
planned dose of radiation. There was one recorded dose
reduction, from 60 Gy to 12 Gy due to radiation compli-
cations (early moist desquamation).
Table 3 Radiation delivery method and dose received by
patients in study (n = 66)




Radiation dose planned n(%) Number of patients
with dose reduction
10-15 Gy 0 (0%) 0
15-20 Gy 0 (0%) 0
20-25 Gy 0 (0%) 0
25-30 Gy 3 (5%) 0
30-35 Gy 1 (2%) 0
35-40 Gy 0 (0%) 0
40-45 Gy 1 (2%) 0
45-50 Gy 6 (9%) 0
50-55 Gy 45 (70%) 0
55-60 Gy 9 (14%) 1 (Reduced to 12 Gy)
60-65 Gy 1 (2%) 0
Median: 51.9 Gy
Range: 25.0-63 Gy Total: 1 (out of 66) (2%)
The radiation dose received by patients in the study and dose reduction, both
as a total number and as a percentage of study participants. Abbreviations:
3D-CRT 3-Dimensional Conformal Radiation Therapy; IMRT Intensity Modulated
Radiation Therapy; Gy gray.
Table 4 Adverse events experienced by patients in the










Case descriptions of grade 3 and 4 toxicity description
(case by case)
Case 1, grade 3 Grade 2 stomatitis, grade 3 diarrhea
Case 2, grade 3 Grade 3 diarrhea, stool incontinence
Case 3, grade 4 Grade 4 diarrhea
Case 4, grade 4 Grade 4 diarrhea, stool incontinence
Case 5, grade 4 Grade 4 diarrhea
The adverse events experienced by patients in the study, including nausea,
vomiting, stomatitis or diarrhea are shown in the top of the table. The lower
half includes a more detailed description of each of the five grade 3 and 4
adverse events.
Table 5 Radiation dermatitis experienced by patients in
this study, by toxicity grade (n = 66)




The breakdown of radiation dermatitis experienced by patients during this
study based on toxicity grade.
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dimensional conformal RT (3D-CRT) was shown to be
the primary technique used, with 50 patients (76%) receiv-
ing this treatment, while the remaining 16 patients (24%)
received intensity-modulated RT (IMRT) (Table 3).
Patient toxicities
Toxicity grades adverse events experienced by patients
are described in Table 4 and include nausea, vomiting
and stomatitis. A total of 54 patients (82%) experienced
grades 0–1 toxicity, including minor changes in bowel
habits, one episode of nausea and vomiting per day as
well as the presence of painless ulcers, erythema or mild
soreness. A total of seven patients (11%) experienced
grade 2 toxicity, including moderate changes in bowel
habits, 2–5 episodes of nausea and vomiting a day and
painful erythema, edema or ulcers. Two patients (3%)
experience grade diarrhea and three patients (5%) were
classified as having grade 4 diarrhea.
Peri-anal radiation dermatitis was experienced in vary-
ing degrees by numerous patients during the course of
treatment (Table 5). Using the Dermatitis Grading Scale
from the BCCA Care of Radiation Skin Reactions [21],
there were a total of 19 patients (29%) that experienced
grade 1 toxicities which encompassed minor skin changes
such as numbness and tingling. Five patients (8%) experi-
enced a grade two toxicity noted by erythema and swelling,and 42 patients (63%) experienced a grade 3 toxicity
highlighted by instances of moist desquamation and
ulceration.Patient outcomes
Median follow-up from time of initial diagnosis was
20 months. Of patients with Squamous cell histology
(N = 62) 94% had no evidence of relapse as of April
2013. Four patients (6%), one stage I, one stage II and
two stage III, had recorded relapses. One relapsed pa-
tient with initial stage II disease died, however, death
was not attributed to treatment. Sorting the outcomes
by cancer stage, one out of 26 patients (4%) with stage
I tumours experienced a local relapse. For patients with
stage II tumors, one out of 15 patients experienced a
distant relapse, with two recorded deaths not attributed
to treatment, and one out of the 25 patients with stage
III tumours experiencing a distant relapse. Among 4 pa-
tients with tubulovillous adenoma and adenocarcinoma
histology, 0% experienced a relapse.
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In this study, the charts of 66 patients with stage I-III
SCC of the anal canal treated at BCCA with multimodality
therapy – Cap, MMC and radiation – were retrospectively
reviewed. Although the global standard of care for SCC of
the anal canal is concurrent radiotherapy with 5-FU and
MMC, a standard protocol substituting infusional 5-FU
with oral capecitabine was introduced in 2010 as an alter-
native non-infusional regimen [20]. Results of the study
showed that while the majority of patients experienced
some form of chemotherapy or radiation induced toxicity,
protocol therapy was well tolerated; despite some dose re-
ductions due to apparent toxicities there were no treatment
discontinuations. The majority of patients who underwent
this therapy since its initiation in 2010 currently have their
tumors in remission with only a few reported cases of
relapses and no treatment-related deaths.
Limitations encountered in this study centered on the
retrospective nature of the collection of toxicity data.
While the number of patients included was modest, the
current study adds to the description of efficacy and out-
comes of this regimen. Results compare favorably to the
previous publication of the phase II study on which the
current GICART protocol was based [19]. To our know-
ledge, there are no other prospective or retrospective
studies describing this treatment regimen.
Patient characteristics
Median age of patients in this cohort was 60 and the
majority of tumors were stage I-II at presentation. It was
noteworthy that there were almost twice as many female
subjects in the study cohort as males. A significant in-
crease in SCC has been documented in both men and
women [22]. Most study subjects did not smoke, and
there was only one HIV-positive subject included in the
cohort. The preferred institutional chemotherapy regi-
men for HIV-positive patients is cisplatin-capecitabine
due to the more favorable hematological toxicity de-
scribed with cisplatin over MMC [6].
Chemotherapy tolerance
Toxicity grades for nausea, vomiting and diarrhea were
low despite the high dose intensity of chemotherapy
drugs administered (Table 4). Most patients experienced
only grade 0–1 toxicities indicating favorable outcomes
with low side effects, while 12 patients (19%) experi-
enced grade 2–4 toxicities for nausea, vomiting and
diarrhea.
Overall, the starting doses of Cap (generally of 825 mg/m2
BID on each radiotherapy day) were well tolerated by the
patients; however, 20% of patients required dose reduc-
tions, likely for reasons of apparent toxicity. A total of 8%
of patients experienced grade 3–4 gastrointestinal toxicities
which would lead to protocol-specified dose reductions.11% experienced grade 2 gastrointestinal and skin toxic-
ities which would require a dose reduction on second
occurrence.
The chart review revealed that while all of the patients
involved in this study experienced some degree of derma-
titis during radiotherapy treatment, only one patient re-
quired radiation dose reduction. Generally, radiation
treatment of any degree causes some sort of reaction in
the treated and neighboring skin layers so the results
themselves are not unexpected given the duration and
intensity of the radiation doses.Radiation therapy
The GICART protocol specified 50.4 Gy in 28 fractions
over 5.5 weeks. A range of treatment schedules, tech-
niques and doses were used to reflect variability in individ-
ual patient factors and tumour characteristics. Generally,
patients with a higher tumour stage or patients physically
able to withstand higher doses of radiation were given lar-
ger radiation doses, while patients with lower stage tumors
were treated with lower radiation doses. In a previous
phase II study, escalating doses of radiation were prospect-
ively defined in the following manner: patients with stage
T1 tumours were given a dose of 45 Gy in 25 fractions,
patients with stage T2 tumours were given a dose of
55 Gy in 30 fractions, and patients with stage T3–4 tu-
mours were given 59 Gy in 32 fractions [23]. Radiation
oncologists involved in the current study used similar cri-
teria to justify dose variation according to tumor stage.
There was no discernible difference in outcomes between
the patients treated with the two radiation techniques,
3D-CRT and IMRT.
All patients included in the study achieved initial re-
mission of disease. Subsequent relapses were infre-
quent and occurred in only 4% of stage I, 7% of stage
II patients and in 6% of patients with stage III disease.
Due to limited follow-up time, no conclusion regard-
ing the efficacy of the regimen can be made at this
time. However, phase III evidence from other disease
settings show equivalence of capecitabine to infusional
5-FU in multiple settings [18,24,25]. One randomized
head-to-head study of infusional 5-FU versus capecita-
bine in combination with radiation for stage II/III rectal
cancer demonstrated equivalent efficacy and toxicity
when given with pelvic radiation at doses of 50.4 Gy
over 28–31 days [16,17].
No significant differences in the rates of pathologic
complete response or grade 3–4 diarrhea were identified
between the infusional 5-FU and versus CAP at a dose
of 825 mg/m2 twice daily, 5 days/wk. Given the favorable
tolerance and high dose intensity for both capecitabine
and radiation described in the current study, it is unlikely
that the substitution capecitabine for infusional 5-FU in
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outcomes.
In this study there was a wide variation in radiation
doses. At this point in time, the variations in adminis-
tered radiation doses do not correlate with different out-
comes, suggesting that lower radiation doses may be
considered in some patients. Longer term follow up of
patients in this cohort is necessary to ensure that pa-
tients who received lower doses of radiation and chemo-
therapy have similar outcomes to those who received
larger doses. Our intention is to follow this cohort to see
if additional correlations between radiation and chemo-
therapy and long term survival outcomes can be made.
Conclusions
Combined modality therapy of capecitabine plus mitomy-
cin and radiotherapy is well tolerated and allows high dose
intensity of radiation and chemotherapy in a population
based setting. Substitution of capecitabine for infusional
5-FU is feasible and may be a reasonable consideration for
patients and physicians who prefer to avoid the inconveni-
ence and potential complications of a central infusional
device. A range of planned radiation doses, schedules and
techniques were employed reflecting tumor and patient
characteristics. Prospective studies to determine optimal
radiation dose would be justified.
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